STOCK TITAN
  1. Home
  2. News
  3. DTCFF

DEFENCE THERAPEUTICS A - DTCFF STOCK NEWS

Welcome to our dedicated page for DEFENCE THERAPEUTICS A news (Ticker: DTCFF), a resource for investors and traders seeking the latest updates and insights on DEFENCE THERAPEUTICS A stock.

Defence Therapeutics Inc. (symbol: DTCFF) is a Canadian biopharmaceutical company specializing in immune-oncology therapeutics and drug delivery technologies. The company recently announced the successful development of its second-generation ARMTM anti-cancer vaccine, ARM-002TM, which has shown therapeutic effectiveness against pre-established melanoma when combined with an anti-PD-1 immune-checkpoint inhibitor. Defence's unique approach involves the use of reprogrammed mesenchymal stromal cells and AccuTOX® to induce potent antigen presentation for enhanced immune response. The ARM-002TM vaccine is highly versatile and adaptable, being tested on

News

Defence to Present Three of Its Leading Products at the Upcoming Festival of Biologics in Basel, Switzerland

Rhea-AI Summary
Defence Therapeutics Inc. to participate in Festival of Biologics in Basel, Switzerland
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

Defence's Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines

Rhea-AI Summary
Defence Therapeutics announces successful results in its encapsulation strategy, with antibody response twice as potent as standard mRNA LNPs. The company plans to conduct additional tests to optimize its mRNA vaccine pipeline. The mRNA therapeutics market is projected to reach $137.59 billion by 2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Defence to Collaborate with Native Ads for Marketing Campaign

Rhea-AI Summary
Defence Therapeutics Inc. has entered into a service agreement with Native Ads Inc. for a marketing campaign with a total retainer of up to US$250,000. 75% of the campaign budget will be allocated to cost per click costs, media buying, and content distribution, while 25% will be allocated for content creation, web development, and advertising creative development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Defence's Broad and Versatile Accum(R) Technology Platform Focus on Cancer Therapeutics

Rhea-AI Summary
Defence Therapeutics continues to bring innovative strategies targeting immune-oncology indications. Their Accum® technology enhances bio-drug efficacy against cancer. ADCs improved potency by 20-100 folds. Partnership with Orano for next-gen ADC therapies. Dual acting vaccine shows 70-100% survival rate. ARM vaccine demonstrates high cure rates in lymphoma and melanoma. AccuTOXTM program halts pre-established cancers and activates immune response. IND filing expected in Q4 2023. Global oncology market valued at USD 208B in 2022, projected to reach USD 628B by 2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Defence's Innovative Therapeutics Featured on Viewpoint with Dennis Quaid

Rhea-AI Summary
Defence Therapeutics to be featured on Viewpoint, a national educational TV show, highlighting breakthroughs in biotechnology and therapeutics innovations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.05%
Tags
none
-
News

Defence Successfully Completes the First Milestone of Its Collaboration Agreement with Orano

Rhea-AI Summary
Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) successfully reached the first milestone in the Collaboration Agreement with Orano Support SAS to develop next-generation radio-immunoconjugates using Defence's intracellular targeting technology. The milestone involves synthesizing the AccuTOXTM peptide containing the DOTA chelator and the Azide moiety. The company aims to develop novel radio-based therapies with higher specificity and selectivity, ensuring increased therapeutic efficacy with lower adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.49%
Tags
none
News

Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthroughs in Biotechnology

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Defence Patent Portfolio at the Forefront of Success

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Defence's Proprietary Accum(TM) Technology for Delivery of CRISPR/Cas Genome-Editing Complexes Patent Application Published

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Defence Manufacturing of AccuTox(TM) CGMP Final Drug Product Optimization for Its Phase I Clinical Trial at City of Hope

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial

FAQ

What is the current stock price of DEFENCE THERAPEUTICS A (DTCFF)?

The current stock price of DEFENCE THERAPEUTICS A (DTCFF) is $0.2732 as of December 17, 2024.

What is the market cap of DEFENCE THERAPEUTICS A (DTCFF)?

The market cap of DEFENCE THERAPEUTICS A (DTCFF) is approximately 19.7M.

Stock DTCFF logo
DEFENCE THERAPEUTICS A

OTC:DTCFF

DTCFF Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

DTCFF Stock Data

19.70M
45.72M
3.8%
Biotechnology
Healthcare
Link
United States of America
Vancouver